Last updated 2026-08-22
- Acquired by AnGes for $250M, Dec 2020
- Raised $61M Series B led by AnGes, Inc., Jan 2020
Total raised
$61.0M
Last: Undisclosed Round 2020-01
Stage
Acquired
Founded
2015
Headcount
30
HQ
, Israel
Sector
Biotechnology
About
Emendo Biotherapeutics is a gene editing company specializing in the development of novel CRISPR-based nucleases for therapeutic applications. Leveraging its proprietary OMNI technology platform, EmendoBio designs highly specific and efficient nucleases that broaden the targetable range of the genome and minimize off-target effects. The company's therapeutic pipeline targets a range of diseases, including severe congenital neutropenia, bone marrow failure, retinitis pigmentosa, and certain cancers.
Funding history · 1 round · $61.0M total
1 event/round · $61.0M Total Funding: $61.0M in Private Equity
Jan 2020
Headcount over time
30 employees (2026-09) · 1 point
Offices
, Israel · HQ / main office
Show all offices (1 more)
- New York, United States
Q&A
- What is Emendo Biotherapeutics' primary focus?
- Emendo Biotherapeutics focuses on DNA Correction and Genome-editing Platforms, developing next-generation gene-editing tools for genetic disorders.
- When was Emendo Biotherapeutics founded?
- Emendo Biotherapeutics was founded in May 2015.
- What is the current status of Emendo Biotherapeutics?
- Emendo Biotherapeutics was acquired by AnGes in December 2020.
- How much funding did Emendo Biotherapeutics raise in total before its acquisition?
- Emendo Biotherapeutics raised a total of $73,000,000.
- Which investors participated in Emendo Biotherapeutics' January 2020 funding round?
- In January 2020, Emendo Biotherapeutics received funding from OrbiMed and Takeda Ventures.
- What is the employee count for Emendo Biotherapeutics?
- Emendo Biotherapeutics has 11-50 employees.
- Where is Emendo Biotherapeutics headquartered?
- Emendo Biotherapeutics is headquartered in Ness Ziona, Israel, with an additional office in New York, USA.
- What is Emendo Biotherapeutics' core technology?
- Emendo Biotherapeutics' core technology involves recombination-based gene-editing solutions that are highly specific and aim for zero off-target effects to repair and eliminate genetic mutations.
Team · 7
David Baram
Founder · President & Chief Executive Officer
Todd Wider
Chairman of the Board & Chief Medical Officer
Christine Silverstein
CFO
Liat Zadikov
EVP, Human Resources
Michal Avidan Gartzman
EVP, Operations
Naoya Satoh
Board Member
Ei Yamada
Director
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Highlights
1 Patents
Tags
genome-editinggene-editingbiopharmaceuticalgenomics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | emendobio.com/ |
|---|---|
| linkedin.com/company/10443839 |
Identifiers & details
| Founded | 2015-5 |
|---|---|
| Employees (exact) | 30 |
| Offices | New York |
| Status reason | Acquired by AnGes on Dec, 2020 |
Acquisitions & public offerings
Acquired by AnGes 2020-12 $250.0M
Radar intelligence
Web history (Wayback)
| Domain | emendobio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515372027 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-01-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — people (1), annual_report (3), violation (1) |
| Registered address | הולצמן חיים 1 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-12 | עדכון בעלי תפקידים |
| 2026-07-07 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-07-07 | עדכון הפרה |
| 2026-07-07 | דו~ח שנתי-הסרת דירקטור |
| 2026-07-07 | דו~ח שנתי-הוספת דירקטור |